Summary
Adrenaline and noradrenaline cause aggregation of human platelets through α-adrenergic receptors, whereas isoprenaline through β-adrenergic receptors can inhibit aggregation. Either type of adrenergic receptors is coupled to platelet adenylate cyclase. Stimulation and inhibition of adenylate cyclase by β-and α-adrenergic stimulants, respectively, had been demonstrated in human platelet lysates. These effects were characterized with regard to the effectiveness of various agonists and antagonists.
Reduction of platelet adenylate cyclase activity was observed only with L-adrenaline and L-noradrenaline. This inhibitory effect, which was increased in the presence of a β-adrenergic blocking agent, was half-maximal at about 1 to 2×10−6 M adrenaline, and maximal inhibition (by 50–60%) was observed at about 3×10−5M. Various other catecholamine and imidazoline derivatives that act as α-adrenergic agonists in other cell types neither induced aggregation nor affected the enzyme activity.
Adrenaline-induced inhibition of platelet adenylate cyclase was prevented by α-adrenergic blocking agents. These compounds inhibited the effects of adrenaline on aggregation and on adenylate cyclase with similar efficacies. Dihydrogenated ergot alkaloids were more effective than phentolamine and yohimbine; phenoxybenzamine, tolazoline and azapetine were least effective. Adrenaline-induced inhibition of platelet adenylate cyclase was reversed by phentolamine without apparent lag phase.
In the presence of α-adrenergic blocking agents, adrenaline was capable of increasing adenylate cyclase activity between 20 and 50%. Only adrenaline and isoprenaline stimulated adenylate cyclase activity; other compounds that stimulate β-adrenergic receptors in other cell types, including β-adrenergic stimulants, had no effect on the activity of the platelet enzyme. The stimulatory effect of adrenaline was prevented by various β-adrenergic blocking agents including pindolol and propranolol. Preferentially β-adrenergic receptor blocking agents such as practolol and atenolol were without effect.
These findings indicate that the spectrum of compounds capable of exhibiting intrinsic activity through α- and β-adrenergic receptors of human platelets is very narrow and that either type of platelet adrenergic receptors appears to differ from those found in other cell types.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdulla, Y. H.: β-Adrenergic receptors in human platelets. J. Ateroscler. Res. 9, 171–177 (1969)
Abe, K., Robison, G. A., Liddle, G. W., Butcher, R. W., Nicholson, W. E., Baird, C. E.: Role of cyclic AMP in mediating the effects of MSH, norepinephrine and melatonin on frog skin color. Endocrinology 85, 674–682 (1969)
Barker, K. A., Harper, B., Hughes, I. E.: Possible subdivisions among α-adrenoceptors in various isolated tissues. J. Pharm. Pharmacol. 29, 129–134 (1977)
Berridge, M. J.: The interaction of cyclic nucleotides and calcium in control of cellular activity. Adv. Cyclic. Nucleotide Res. 6, 1–98 (1975)
Berthelsen, S., Pettinger, W. A.: A functional basis for classification of α-adrenergic receptors. Life Sci. 20, 595–606 (1977)
Born, G. V. R.: Aggregation of human platelets by adenosine diphosphate and its reversal. Nature 194, 927–929 (1962)
Boyd, H., Martin, T. J.: Changes in catecholamine- and glucagon-responsive adenylate cyclase activity in paraneoplastic rat liver. Mol. Pharmacol. 12, 195–202 (1976)
Burns, T. W., Langley, P. E., Robinson, G. A.: Studies on the role of cyclic AMP in human lipolysis. Adv. Cyclic. Nucleotide Res. 1, 63–85 (1972)
Cole, B., Robison, G. A., Hartmann, R. C.: Studies on the role of cyclic AMP in platelet function. Ann. N.Y. Acad. Sci. 185, 477–487 (1971)
Gorman, R. R., Bunting, S., Miller, O. V.: Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13, 377–388 (1977)
Harwood, J. P., Moskowitz, J., Krishna, G.: Dynamic interactions of prostaglandin and norepinephrine in the formation of adenosine 3′,5′-monophosphate in human and rabbit platelets. Biochim. Biophys. Acta 261, 444–456 (1972)
Haslam, R. J., Lynham, J. A.: Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloroadenosine. Life Sci. 11, Part II. 1143–1154 (1972)
Haslam, R. J., Taylor, A.: Effects of catecholamines on the formation of adenosine 3′:5′-cyclic monophosphate in human blood platelets. Biochem. J. 125, 377–379 (1971)
Jakobs, K. H., Saur, W., Schultz, G.: Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic component of epinephrine. J. Cycl. Nucl. Res. 2, 381–392 (1976)
Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265–275 (1951)
Marquis, N. R., Becker, J. A., Vigdahl, R. L.: Platelet aggregation. III. An epinephrine induced decrease in cyclic AMP synthesis. Biochem. Biophys. Res. Commun. 39, 783–789 (1970)
Mills, D. C. B., Macfarlane, D. E.: Stimulation of human platelet adenylate cyclase by prostaglandin D2. Thromb. Res. 5, 401–412 (1974)
Mills, D. C. B., Roberts, G. C. K.: Effects of adrenaline on human blood platelets. J. Physiol. 193, 443–453 (1967)
Nakai, C., Brooker, G.: Assay for adenylate cyclase and cyclic nucleotide phosphodiesterases and preparation of high specific activity 32P-labeled substrates. Biochim. Biophys. Acta 391, 222–239 (1975)
O'Brien, J. R.: Some effects of adrenaline and anti-adrenaline compounds on platelets in vitro and in vivo. Nature 200, 763–764 (1963)
O'Brien, J. R.: A comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors. J. Clin. Pathol. 17, 275–281 (1964)
Robison, G. A., Arnold, A., Hartmann, R. C.: Divergent effects of epinephrine and prostaglandin E1 on the level of cyclic AMP in human blood platelets. Pharmacol. Res. Commun. 1, 325–332 (1969)
Robison, G. A., Butcher, R. W., Sutherland, E. W.: Adenyl cyclase as an adrenergic receptor. Ann. N.Y. Acad. Sci. 139, 703–723 (1967)
Robison, G. A., Butcher, R. W., Sutherland, E. W.: Cyclic AMP, pp. 145–231. New York: Academic Press 1971
Sabol, S. S., Nirenberg, M.: Norepinephrine inhibits adenylate cyclase of neuroblastoma X glioma hybrid cells via alpha-adrenergic receptors and converts cells to a norepinephrine-dependent state. Fed. Proc. 36, 736 (1977)
Salzman, E. W., Neri, L. L.: Cyclic 3′,5′-adenosine monophosphate in human blood platelets. Nature 224, 609–610 (1969)
Symons, R. H.: Synthesis of [α-32P]ribo- and deoxyribonucleoside 5′-triphosphates. Methods Enzymol. 29, 102–115 1974
Turtle, J. R., Kipnis, D. M.: An adrenergic receptor mechanism for the control of cyclic 3′,5′-adenosine monophosphate synthesis in tissues. Biochem. Biophys. Res. Commun. 28, 797–803 (1967)
Watanabe, A. M., Hathaway, D. R., Besch, H. R., Jr., Farmer, B. B., Harris, R. A.: α-Adrenergic reduction of cyclic adenosine monophosphate concentrations in rat myocardium. Circ. Res. 40, 596–602 (1977)
Wolfe, S. M., Shulman, N. R.: Adenyl cyclase activity in human platelets. Biochem. Biophys. Res. Commun. 35, 265–272 (1969)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jakobs, K.H., Saur, W. & Schultz, G. Characterization of α- and β-adrenergic receptors linked to human platelet adenylate cyclase. Naunyn-Schmiedeberg's Arch. Pharmacol. 302, 285–291 (1978). https://doi.org/10.1007/BF00508297
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00508297